Skip to content

Sedation, Temperature and Pressure after Cardiac Arrest and Resuscitation

Sedation, Temperature and Pressure after Cardiac Arrest and Resuscitation - the STEPCARE trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON57797
Enrollment
130
Registered
2025-06-19
Start date
2025-07-20
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ICU treatment after a cardiac arrest optimal treatment after cardiac arrest

Interventions

Screening and randomization Screening can be performed either in the emergency room, angiography suite, or in the ICU. Clinical investigators at each participating site will be responsible for scree

Sponsors

Department ofAnesthesiology and IntensiveCare, Helsingborg Hospital Department of Clinical Sciences, Lund University, Faculty of Medicine
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1.Out-of-hospital cardiac arrest of non-traumatic origin 2. A minimum of 20 minutes without chest compressions* 3. Unconsciousness defined as not being able to obey verbal commands (FOUR-score motor response of

Exclusion criteria

Exclusion criteria: 1. On ECMO prior to randomization 2. Pregnancy 3. Suspected or confirmed intracranial hemorrhage 4. Previously randomized in the STEPCARE trial

Design outcomes

Primary

MeasureTime frame
We will investigate the following main hypotheses: • In adults who are comatose following resuscitation from out-of-hospital cardiac arrest continuous sedation for 36 hours leads to lower six-month mortality than minimal se-dation. • In adults who are comatose following resuscitation from out-of-hospital cardiac arrest, fever management with a device leads to a lower mortality than fever management without a feedback-controlled device. • In adults who are comatose following resuscitation from out-of-hospital cardiac arrest, targeting a mean arterial pressure of >85 mmHg leads to a lower mortality than target-ing a mean arterial pressure of >65 mmHg. Primary Outcome: All-cause mortality assessed at 6 months after randomization

Secondary

MeasureTime frame
• Proportion of participants with a poor functional outcome measured in either one of two ways (hierarchical order): 1.Using the clinician reported modified Rankin Scale (mRS)-scale (mRS 4-6) at 6 months after randomization 2. If a score cannot be assigned using the standardized assessment patients with be categorized based on whether they are found to be dependent on others for basic ac-tivities of daily life (moving indoors, eating, dressing, personal hygiene) • Patient reported Health-Related Quality of Life (HRQoL) using EQ5D-5L including EQVAS at 6 months after randomization. • Proportion of patients who had a pre-defined safety event or death in the ICU. (For each trial) o SED-CARE: sepsis or septic shock (Sepsis III criteria), arrhythmia requiring defibrillation, cardioversion or chest compressions, venous thromboembolism,reintubation, non-planned extubation o TEMP-CARE: sepsis or septic shock (Sepsis III criteria), arrhythmia requiring defibrillation, cardioversion or chest compressions, venous thromboembolism, moderate or severe bleed-ing (GUSTO criteria) o MAP-CARE: arrhythmia requiring defibrillation, cardioversion or chest compressions, mod-erate or severe bleeding (GUSTO criteria), acute kidney injury with renal replacement thera-py, limb ischemia requiring radiological or surgical intervention, or gut ischemia demonstrated at laparotomy/laparoscopy or clinically suspected based on abdominal CT-scan or in the con-text of palliative management. Exploratory outcomes • Ventilator free days within the first 30 days • Hospital/institution free days alive within the first 30 days

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Apr 17, 2026